Spontaneous remission in low-risk forms of prostate cancer

The issue of spontaneous remission of low-risk forms of prostate cancer came up yesterday during a meeting of Prostate Cancer International’s Active Surveillance Virtual Support Group (ASVSG). … READ MORE …

Ductal adenocarcimoma of the prostate is “rare” but aggressive

Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …

Agent Orange and prostate cancer-specific survival on ADT

A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …

PREDICT Prostate: a new, sophisticated, prostate cancer prognostic tool

A new paper just published in PLOS Medicine describes the development of a new online tool called PREDICT Prostate. … READ MORE …

PCF publishes updated patient handbook

The Prostate Cancer Foundation (PCF) has just published the 2019 update to its Prostate Cancer Patient Guide, which is a very useful (and free) introduction to prostate cancer for patients and their caregivers. … READ MORE …

Risk for suicide among prostate cancer patients

An article just published in the journal Cancer states that — at least here in the USA — there was no significant increase in risk for suicide within the first year after diagnosis among men diagnosed with prostate cancer between 2000 and 2014 … READ MORE …

PCaI appoints new Medical Director

This morning, Prostate Cancer International (PCaI) announced the appointment of Michael B. Williams, MD, as its Medical Director and as a member of the Board of Directors of the foundation. … READ MORE …

What prostate cancer awareness means to Dr. Alicia Morgans

Alicia Morgans, MD, MPH, is a medical oncologist who specializes in prostate cancer management at Northwestern University Feinberg School of Medicine in Chicago, Illinois, where she is an associate professor in the Division of Hematology/Oncology. She is also an editor of the Advanced Prostate Cancer Center of Excellence for the UroToday web site. … READ MORE …

Why do men get prostate cancer?

The answer to this question, some 70 to 80 years after we started to see if we could answer it, is still: “We haven’t got a clue.” But every so often people come up with a new or a revised hypothesis, and it can take years to work out whether each specific hypothesis is viable. … READ MORE …

The future of the Prostate Problems Mailing List

For more than 20 years, the Prostate Problems Mailing List (PPML) has been one of the primary forms of intercommunication service between members of the prostate cancer patient community, and it still has about 1,000 members today. … READ MORE …

“Is prostate cancer screening right for you?”

The following infographic was also issued today by the U.S. Preventive Services Task Force (USPSTF) and offers guidance as to the appropriateness of prostate cancer screening for an average, 55- to 69-year-old American male with no specific, known risk factors for prostate cancer: … READ MORE …

When is whole pelvic radiation needed for salvage post-prostatectomy?

Patients who elect to have post-prostatectomy radiation therapy for recurrent prostate cancer face a couple of important decisions: … READ MORE …

Enter the “director of prostate imaging” (at least at some centers)

As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …

Can phi density accurately predict risk for clinically significant prostate cancer?

A new article in BJU International has suggested the possibility that Prostate Health Index density (i.e., a patient’s phi score divided by his prostate volume) may be able to predict the probability of a finding of clinically significant prostate cancer on biopsy. … READ MORE …

Another step toward a rational, risk-stratified PSA testing methodology

A newly published article in the Journal of Clinical Oncology has suggested that PSA testing between 40 and 59 years of age may be able to predict for risk of clinically significant prostate cancer later in life. … READ MORE …